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Abstract
Objective: This investigation assessed the effect of serum estradiol levels on outcomes of in-vitro fertilization
and embryo transfer (IVF) cycles.
Materials and Method: This was a retrospective cohort study of 1123 IVF cycles comparing impact of
estradiol (E2) levels on follicular development, fertilization, embryo quality, implantation, pregnancy rate,
miscarriage rate, and selected obstetric complications.
Results: We found high serum E2 levels to be significantly associated with increased number of mature
follicles and mature oocytes retrieved (p<0.01, for both). E2 levels were also associated with more viable and
good-quality embryos (p<0.01). There was no significant impact of E2 on oocyte maturation, fertilization rate,
embryo quality, or overall pregnancy rates. Moreover, high E2 levels were significantly associated with higher
implantation rates and reduced incidence of miscarriage (p<0.05, for both).
Conclusion: Within the safety range in clinical practice, our data demonstrate a generally positive effect of
high serum E2 on selected IVF parameters.
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Introduction
In the clinical practice of in-vitro fertilization and embryo
transfer (IVF), controlled ovarian hyperstimulation
(COH) is a common technique to maximize the number
of mature oocytes retrieved. This approach must be bal-
anced with the recognized risks of ovarian hyperstimula-
tion syndrome (OHSS), which can result if follicular
recruitment is too robust. Together with the multifollicular
development, COH is inevitably associated with a supra-
physiological serum level of E2 which in turn may affect
endometrial receptivity [1]. The elevated serum E2 estra-
diol levels during COH may therefore be associated either
with an increased chance of pregnancy (reflecting a better
ovarian response), or an impaired reproductive outcome
secondary to altered endometrial receptivity.
Possible associations between serum E2 levels and IVF
outcomes have been the focus of research interest for
many years. Several studies have illustrated the detrimen-
tal effect of high serum E2 levels on IVF outcome [2,3]
although this finding has not been confirmed in others [4–
8]. Indeed, some investigators have noted that serum E2
can positively predict IVF outcomes via the retrieval of a
greater number of oocytes [9–11]. Conflicting results of
previous publications might be related to differences in
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noutcome measures as well as threshold values used to
define “high” E2 levels. While most investigators have
focused on the implantation and pregnancy rates which
are only the final steps, an IVF cycle indeed involves a
sequence of highly synchronized events each of which
must proceed optimally. Not only endometrial receptivity
and embryo implantation, but also follicular development,
fertilization, and embryo quality are all important keys for
determining success of an IVF cycle.
This study aims to present a comprehensive assessment of
the impact of serum E2 on the different components of an
IVF cycle. We compare the impact of serum estradiol lev-
els measured on the day of ovulatory dose of human cho-
rionic gonadotrophin (hCG) on follicular development,
fertilization, embryo quality, implantation, pregnancy
rate, miscarriage rate, and complications such as OHSS.
Methods
This retrospective cohort study encompassed 1123 IVF
cycles performed during January 2005 to December 2007
at the Assisted Reproductive Unit (Hong Kong). This is
the tertiary referral centre affiliated with the Department
of Obstetrics and Gynecology, The Chinese University of
Hong Kong. Since there was no human subjects tested or
interviewed specifically for the purpose of this investiga-
tion, it was determined that IRB approval was not required
for our retrospective study. All IVF cycles performed dur-
ing the above period were analyzed; no cases were exclu-
ded. The causes of infertility for women undergoing IVF
cycles included tubal, male, endometriosis, unexplained
and mixed factors. Intracytoplasmic sperm injection
(ICSI) was carried out in couples with severe semen
abnormalities.
Controlled Ovarian Hyperstimulation (COH)
Protocol
All subjects received a standard protocol for ovulation
induction. Pituitary suppression was achieved via long
(luteal) gonadotropin releasing hormone agonist (GnRHa)
down-regulation protocol. Buserelin nasal spray (Supre-
cur, Hoechst, Germany) 600 mcg daily was administered
for at least 14d from the mid-luteal phase of the preceding
cycle. Complete pituitary desensitization was confirmed
by low serum luteinizing hormone (LH < 10 IU/L) and
estradiol (E2 < 200 pmol/L) concentrations. Patients also
had an ultrasound examination to exclude functional ovar-
ian cysts and verify that endometrial thickness was <5mm.
Once adequate downregulation was confirmed, ovarian
stimulation commenced with human menopausal gona-
dotropins (hMG) (Pergonal, Serono, Aubonne/Switzer-
land) or recombinant follicle stimulating hormone (rFSH)
(Gonad-F, Serono, Aubonne/Switzerland; or Puregon,
Organon, Oss, Holland). For patients undergoing their
first IVF cycles, initial doses of hMG (or equivalent dose
of rFSH) were 225, 300, or 375IU/d for female age groups
of < 33yrs, 33–35yrs, and >35yrs, respectively. The start-
ing dose was reduced to 150IU/d for anticipated high res-
ponders (i.e., PCO patients). Alternatively, baseline gona-
dotropin dose was increased to 450IU/d for anticipated
poor responders, such as those with elevated basal serum
FSH levels. For patients undergoing subsequent IVF
cycles, the starting doses were influenced by ovarian
response in the prior cycle/s as well as patient age. Neither
antral follicle count nor ovarian volume was considered
in dose determination.
Ovarian response was monitored by transvaginal ultra-
sound and serum E2 concentrations from stimulation day
6 onwards. The dose of gonadotropins was adjusted during
the stimulation depending on the ovarian response. When
follicular recruitment was considered adequate (defined
by the presence of at least three mature follicles 18mm in
diameter), an ovulatory dose of hCG (Profasi, Serono,
Aubonne/Switzerland) 5,000 IU was given and transva-
ginal oocyte retrieval was performed approximately 36h
later. All patients received a titrated dose of diazepam and
pethidine for analgesia. For patients with poor ovarian
response (defined as less than three mature follicles on
ultrasound), the cycle was cancelled and retrieval was not
attempted. Embryo transfer was performed three days
after oocyte retrieval and surplus embryos were cryopre-
served. Patients undergoing embryo transfer received
intramuscular hCG or vaginal progesterone for luteal
phase support beginning on the day of oocyte retrieval.
For those with excessive ovarian response (defined as >20
oocytes retrieved, or 15–20 oocytes retrieved but with risk
factors for OHSS such as known PCO or past history of
OHSS), all viable embryos were cryopreserved instead so
as to minimize the risk of OHSS.
Outcome Measures
IVF cycle outcome was assessed by urine pregnancy test
performed 10d after the final dose of hCG (luteal phase
support) or two weeks after embryo transfer, whichever
occurred later. If a positive test was reported, vaginal
ultrasound of the pelvis would be performed two weeks
later to assess the site, the number, and the viability of
gestation. Pregnancy rate was defined as positive urine
pregnancy test per embryo transfer, while implantation
rate was defined as number of gestational sacs per embryo
transferred. The pregnancy outcomes, such as miscarriage
and live birth were also recorded, along with multiple ges-
tation rate and complications.
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nClotted blood samples (5ml) were collected by peripheral
venipuncture at the conclusion of follicular recruitment
(on the day of ovulatory dose of hCG) for serum E2 meas-
urements. Serum estradiol levels were quantified by using
a competitive immunoassay with direct chemiluminesent
technology (Bayer, Tarrytown, NY, USA). Interassay
coefficients of variation of the assay were 9.8%, 4.2%, and
8.7% at concentrations of 250, 859, and 2830 pmol/L
respectively.
Data on patient characteristics, ovarian stimulation proto-
col and embryology were also collected. These included
ages of patients, type, duration, and cause of infertility,
ovarian reserve assessment (CD#3 serum FSH levels),
number of previous IVF cycles, duration and total dose of
gonadotropin treatment, endometrial thickness on day of
ovulatory hCG, number of ovarian follicles >15 mm in
diameter, number of mature oocytes and total oocytes
retrieved, fertilization rate, and number of viable embryos
and good-quality embryos (which were defined as four-
cell or more cleaved embryos, seven-cell or more cleaved
embryos and blastocysts transferred 48h, 72h and 120h
after retrieval, respectively). The number of embryos
transferred per patient was also reviewed.
Statistics
Statistical analysis was carried out using SPSS (version
16). Continuous data were expressed as mean ± standard
deviation (SD). One-way analysis of variance (ANOVA)
with Bonferroni correction for multiple comparisons was
used to analyze continuous data and chi-square test was
used to analyze categorical data, where appropriate.
P<0.05 was considered statistically significant.
Results
A total of 1123 IVF cycles were studied. Among them,
418 (37.2%) cycles had ICSI performed for severe semen
abnormalities; 607 (54.1%) cycles were the first IVF trial
for the women. The women aged 35.8 ± 3.7 years and the
baseline serum FSH level was 7.7 ± 2.7 mmol/L. Con-
cerning the outcomes, the mean (±SD) number of total
oocytes and mature oocytes retrieved per cycle were 9.8
± 5.6 and 7.8 ± 4.6, respectively. Mean (±SD) number of
viable embryos and good embryos per cycle were 2.7 ±
2.2 and 2.0 ± 2.1, respectively. The overall implantation
rate was 22.6% while the overall pregnancy rates per cycle
initiated, per cycle with oocyte retrieval, and per cycle
with embryo transfer were 31%, 31% and 36%, respec-
tively.
The mean, 25 percentile, median and 75 percentile of
serum E2 levels on day of hCG administration were
13,200, 6000, 10500 and 17300 pmol/l, respectively.
Based on these percentiles, the IVF cycles were catego-
rized into four groups: Group 1 (243 cycles with E2 < 6000
pmol/L), Group 2 (393 cycles with E2 = 6000–12000
pmol/L), Group 3 (231 cycles with E2 = 12000–18000
pmol/L), and Group 4 (256 cycles with E2 > 18000 pmol/
L). In Group 4 (the high responder group), 54 cycles (20%)
underwent elective cryopreservation of all embryos in
view of anticipated high risk of OHSS. Among them, 18
(33%) cycles did develop OHSS. The incidence of OHSS
for the whole cohort was 12.5% (140 cycles), and 1.2%
(13 cycles) were severe cases.
Women in Group 4 were younger (34.7 ± 3.5 vs. 37.0 ±
3.8 & 35.8 ± 3.6yrs, p<0.01), had lower average baseline
FSH level (6.7 ± 1.6 vs. 8.7 ± 2.9 & 7.9 ± 2.6 IU/L, p<0.01)
and consumed a lower gonadotropin dose during IVF
(3021.4 vs. 4352.9 & 3824.4 IU, p<0.01) compared to
patients in Group 1 and 2, respectively. However, there
were no significant differences among the groups in other
potential covariates, including frequency of PCO diagno-
sis, number of previous IVF cycles, fertilization method,
and cancellation rate due to poor ovarian response (see
Table 1).
Follicular development in Group 4 demonstrated an
increased number of follicles >15mm in diameter (12.4 ±
3.7 vs. 4.4 ± 1.9, 6.9 ± 2.6 & 9.3 ± 3.2, p< 0.01), more
oocytes retrieved (15.3 ± 6.1 vs. 5.3 ± 3.0, 8.3 ± 3.6 & 10.9
± 4.5, p< 0.01), and a higher average number of mature
oocytes retrieved (12.2 ± 5.1 vs. 4.3 ± 2.6, 6.6 ± 3.0 & 8.7
± 3.8, p< 0.01) compared to s 1, 2 and 3, respectively.
However, there were no significant differences among
study groups regarding oocyte maturation rate or average
number of cycles where poor oocyte quality was observed
(see Table 2).
The fertilization rate was 60%, which was not signifi-
cantly different among these 4 groups with different E2
levels. However, IVF cycles in Group 4 had a higher mean
number of viable embryos (3.9 ± 3.1 vs. 1.7 ± 1.5 & 2.5 ±
1.7, p<0.01), a higher average number of good embryos
(2.9 ± 2.8 vs. 1.2 ± 1.4 & 1.8 ± 1.7, p<0.01), but a reduced
proportion of viable embryos per fertilized oocyte (0.49 ±
0.27 vs. 0.58 ± 0.36 & 0.58 ± 0.30, p< 0.01) compared to
Group 1 and 2, respectively. However, there were no sig-
nificant differences in proportion of good embryos per
fertilized oocyte among the study groups (see Table 2).
There were no significant differences in pregnancy rates,
live birth rates per cycle, or miscarriage and multiple ges-
tation rates per pregnancy among the four groups. How-
ever, IVF cycles in Group 4 demonstrated a higher implan-
tation rate (0.28 ± 0.38 vs. 0.20 ± 0.33, p=0.04) compared
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nto Group 2. Also, Group 4 was associated with lower mis-
carriage rate (12.2 vs. 23.6% & 24.2 %, p<0.05) compared
to Groups 1 and 2, respectively. As expected, the compli-
cation rate of OHSS was significantly higher in Group 4
(22 vs. 4.5% & 9.7%, p< 0.01) compared to Groups 1 and
2, respectively (see Table 3).
For the sub-set of patients with extremely high E2 levels
accompanied by elective embryo cryopreservation (no
fresh transfer), these cycles were associated with more
follicles, more total oocytes retrieved, more mature
oocytes retrieved and more viable embryos. However,
oocyte maturation, number of cycles with poor oocyte
quality, fertilization rate, proportion of viable embryos per
fertilized oocyte, number of good quality embryos, and
proportion of good embryos per fertilized oocyte were not
significantly different from the other 4 groups.
A subgroup analysis was also performed for patients with
a favorable prognosis, (i.e., those age <38yrs and with
CD#3 FSH level <10mmol/L). A total of 664 IVF cycles
met this criteria and were eligible for analysis; these were
stratified into four categories according to the same E2
threshold levels as used in the overall analysis. Tables 4
and Table 5 summarize IVF outcomes in this subgroup of
favorable prognosis patients. The results were similar to
Table 1:
Patient characteristics observed among four groups of in-vitro fertilization cycles as a function of serum estradiol.
Characteristics
  Group 1 (n=243)
  Group 2 (n=393)
  Group 3 (n=231)
  Group 4 (n=256)
 
Age (yrs) 37.0 ± 3.8# 35.8 ± 3.6# 35.5 ± 3.5 34.7 ± 3.5
Day 3 FSH (IU/L) 8.7 ± 2.9# 7.9 ± 2.6# 7.1 ± 1.9 6.7 ± 1.6
PCO 4 (1.6%) 22 (5.6%) 11 (4.8%) 16 (6.3%)
First trial of IVF 122 (50.2%) 211 (53.7%) 115 (49.8%) 159 (62.1%)
Fertilization with ICSI 89 (36.6%) 152 (38.7%) 84 (36.4%) 93 (37.2%)
Total dose of gonadotropin
(IU) 4353# 3824# 3512* 3021
Cancellation of cycle
  3 (1.2%)
  1 (0.3%)
  1 (0.4%)
  1 (0.4%)
 
Values are numbers (percentages) of cycles or mean ± standard deviation.
n = number of cycles of in-vitro fertilization
FSH: Follicle stimulation hormone
PCOS: Polycystic ovary syndrome
IVF: In vitro fertilization
ICSI: Intracytoplasmic sperm injection
*
(p<0.05) and
#
(p<0.01) indicate significant differences vs. Group 4
Table 2:
Follicular development, fertilization and embryo quality in various groups of in vitro fertilization cycles with different
serum estradiol levels
Outcome
  Group 1 (n=243)
  Group 2 (n=393)
  Group 3 (n=231)
  Group 4 (n=256)
 
Number of follicles >15mm 4.4 ± 1.9# 6.9 ± 2.6# 9.3 ± 3.2# 12.4 ± 3.7
Number of total oocytes
retrieved 5.3 ± 3.0# 8.3 ± 3.6# 10.9 ± 4.5# 15.3 ± 6.1
Number of mature oocytes
retrieved 4.3 ± 2.6# 6.6 ± 3.0# 8.7 ± 3.8# 12.2 ± 5.1
Maturation rate per oocyte
retrieved 0.81 ± 0.19 0.80 ± 0.18 0.80 ± 0.14 0.80 ± 0.15
Cycles with poor oocyte qual-
ity 118(48.6%) 186(47.3%) 110(47.6%) 104(40.6%)
Fertilization rate 0.61 ± 0.32 0.62 ± 0.27 0.59 ± 0.26 0.61 ± 0.25
Number of total viable
embryos 1.7 ± 1.5# 2.5 ± 1.7# 2.8 ± 1.9# 3.9 ± 3.1
Viable embryo per fertilized
oocyte 0.58 ± 0.36# 0.58 ± 0.30# 0.52 ± 0.29 0.49 ± 0.27
Number of good quality
embryos 1.2 ± 1.4# 1.8 ± 1.7# 2.0 ± 1.8# 2.9 ± 2.8
Good quality embryos per
fertilized oocyte
 
0.39 ± 0.36
  0.38 ± 0.31
  0.35 ± 0.29
  0.36 ± 0.28
 
Values are numbers (percentages) of cycles, or mean ± standard deviation.
n = number of cycles of in vitro fertilization
#
(p<0.01) indicates significant differences from Group 4
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nthe overall group, but with significant improvement in
follicular development and number of embryos. There was
also a reduced rate of miscarriage (but an increased risk
of OHSS) in Group 4 compared to Groups 1 and 2. How-
ever, there were no significant differences among groups
in fertilization rate, implantation rate, pregnancy and live
birth rates per cycle, or miscarriage and multiple gestation
rates.
Discussion
It is well established that E2 is essential in an IVF cycle
by protecting developing follicles from atresia and stim-
ulating endometrial growth for subsequent implantation
and further pregnancy. However, the associations between
various serum E2 levels and particular IVF outcomes have
remained controversial. Low serum estradiol level is appa-
Table 3:
Implantation, pregnancy, and live birth rates of in vitro fertilization cycles, including miscarriage and multiple gestation
rates per pregnancy, and incidence of OHSS according to serum estradiol level.
Outcome
  Group 1 (n=243)
  Group 2 (n=393)
  Group 3 (n=231)
  Group 4 (n=256)
  EC (n=54)
 
Implantation rate 0.23 ± 0.35 0.20 ± 0.33* 0.21 ± 0.35 0.28 ± 0.38 --
Pregnancy per initiated
cycle 72/243 (29.6%) 120/393 (30.5%) 71/231 (30.7%) 82/256 (32.0%) --
Pregnancy per OR 72/240 (30.0%) 120/387 (31.0%) 71/229 (31.0%) 82/255 (32.2%) --
Pregnancy per ET 72/196 (36.7%) 120/357 (33.6%) 71/209 (34.0%) 82/186 (44.1%) --
Live birth per ET 53/196 (27.0%) 83/357 (23.2%) 57/209 (27.3%) 68/186 (36.6%) --
Miscarriage per preg-
nancy 17/72 (23.6%)* 29/120 (24.2%)* 7/71 (9.9%) 10/82 (12.2%) --
Multiple gestation rate
per pregnancy 16/72 (22.2%) 25/120 (20.8%) 19/71 (26.8%) 31/82 (37.8%) --
OHSS
  11/243 (4.5%)#
  38/393 (9.7%)#
  35/231 (15%)
  56/256 (22%)
  18/54 (33%)
 
Values are numbers (percentages) of cycles or mean ± standard deviation.
n = number of cycles of in-vitro fertilization
EC: Elective cryopreservation of all embryos
OR: Oocyte retrieval
ET: Embryo transfer
OHSS: Ovarian hyperstimulation syndrome
*
(p<0.05) and
#
(p<0.01) indicate significant differences vs. Group 4
Table 4:
Follicular development, fertilization and embryo quality parameters as a function of serum estradiol level among
favorable prognosis IVF patients.
Outcome
  Group 1 (n = 97)
  Group 2 (n = 226)
  Group 3 (n = 146)
  Group 4 (n = 195)
  EC (n=46)
 
Number of follicles >
15mm 5.0 ± 2.3# 7.2 ± 2.7# 9.4 ± 3.1# 12.4 ± 3.7 15.3 ± 4.2
Number of total oocytes
retrieved 6.0 ± 3.3# 8.4 ± 3.7# 11.0 ± 4.6# 15.3 ± 6.0 21.6 ± 6.1
Number of mature
oocytes retrieved 5.0 ± 2.9# 6.6 ± 3.0# 8.9 ± 3.9# 12.3 ± 5.0 17.1 ± 5.4
Maturation per oocyte
retrieved 0.82 ± 0.17 0.79 ± 0.18 0.81 ± 0.14 0.81 ± 0.14 0.79±0.11
Cycles with poor oocyte
quality 46 (47.4%) 96 (42.5%) 64 (43.8%) 79 (40.5%) 15(32.6%)
Fertilization rate 0.65 ± 0.29 0.61 ± 0.28 0.59 ± 0.27 0.61 ± 0.25 0.61±0.22
Number of total viable
embryos 2.1 ± 1.8# 2.4 ± 1.7# 2.8 ± 2.0# 3.9 ± 3.1 6.4 ± 4.3
Viable embryo per fer-
tilized oocyte 0.56 ± 0.33 0.57±0.30* 0.52 ± 0.29 0.48 ± 0.26 0.59±0.29
Number of good quality
embryos 1.7 ± 1.7# 1.8 ± 1.7# 2.1 ± 1.9# 3.0 ± 2.9 4.5 ± 4.0
Good quality embryos
per fertilized oocyte
 
0.44 ± 0.35
  0.39 ± 0.32
  0.37 ± 0.30
  0.36 ± 0.28
  0.40±0.31
 
Values are numbers (percentages) of cycles, or mean ± standard deviation.
n = number of cycles of in-vitro fertilization
EC: Elective cryopreservation of all embryos
#
(p<0.01) indicates significant difference vs. Group 4
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nrently associated with poor IVF outcomes. However, the
possible adverse impact of elevated serum E2 level on the
IVF outcomes is still under debate. A meta-analysis pub-
lished in 2004 regarding the associations between serum
estradiol level on day of hCG administration and preg-
nancy after IVF drew no conclusions [12]. The current
available evidence, though reasonably extensive, does
bring some limitations with the difference in the cut-off
values for E2 level being the obvious concern.
Earlier work has shown that high serum E2 levels in the
setting of IVF might indicate increased ovarian response
[9–11], increased risk of OHSS [11] and/or reduced endo-
metrial receptivity [2,3]. Indeed, serum E2 level measured
on day of ovulatory dose of hCG is a common clinical
indicator for elective cryopreservation of all viable
embryos as a prophylactic measure to reduce risk of
OHSS, although different assisted reproductive centres
have developed different E2 threshold levels for this. Stud-
ies with lower cut-off for serum E2 level above which all
embryos were cryopreserved could demonstrate the
impact of E2 level on ovarian response only, but not its
impact on OHSS development or endometrial receptivity.
However, it would be unethical to place patients at risk of
developing severe OHSS by allowing fresh embryo trans-
fer in cycles with an extremely high serum E2 level to
reveal the impact on endometrial receptivity. The inci-
dence of severe OHSS in our unit during the study period
was 1.2%. Within this safety range in clinical practice, our
retrospective study has evaluated the impact of serum E2
levels on day of hCG administration on the outcomes from
IVF in a comprehensive manner.
The relatively higher serum E2 levels measured from con-
trolled ovarian hyperstimulation reflected a better ovarian
response of IVF, and as expected, these cycles were from
patients with better ovarian reserve as suggested by their
younger ages and lower baseline FSH levels. Most impor-
tantly, our study has observed a negative relationship
between the consumption of gonadotropin and serum E2
levels at the time of hCG administration. This finding
suggests that a high E2 level is not necessarily a result of
high-dose gonadotrophin stimulation. Indeed, for women
with good ovarian reserve, the lower dose of gonadotro-
phin is enough to trigger an adequate ovarian response
with high serum E2 levels. Therefore, the dosage of gona-
dotrophin used in controlled ovarian hyperstimulation
should be adjusted, especially for women with good prog-
nostic factors so as to avoid further increase in serum
estradiol level which may result in potential detrimental
effect on the IVF cycle and OHSS.
Although the incidence of severe OHSS (1.2%) in our unit
during the study period was acceptable, the incidence of
overall OHSS was too high. After this retrospective anal-
ysis, we reevaluated our practice and implemented some
changes to reduce the risk of OHSS. Specifically, we have
modified the starting doses of gonadotropin to be calibra-
ted not only by patient age and previous treatment
response, but also by antral follicle count. This has resul-
ted in starting doses of gonadotropins now being lower for
most paitents. Coasting in selected cycles with high risk
of OHSS will also be considered, all IVF patients will have
vaginal progesterone (rather than intramuscular hCG) for
luteal phase support.
In agreement with previous studies which showed the
relationship between high serum E2 level and good ovar-
ian response [9–11], our data demonstrate the improve-
ment of follicular development as well as the quality and
Table 5:
Implantation rate, pregnancy and live birth rates per cycle (including miscarriage and multiple gestation rates) observed
in favorable prognosis IVF patients as a function of serum estradiol level.
Outcome
  Group 1 (n = 97)
  Group 2 (n = 226)
  Group 3 (n = 146)
  Group 4 (n = 195)
 
Implantation rate 0.30 ± 0.38 0.24 ± 0.36 0.26 ± 0.37 0.34 ± 0.39
Pregnancy per initiated cycle 39/97 (40.2%) 80/226 (35.4%) 50/146 (34.2%) 69/195 (35.4%)
Pregnancy per OR cycle 39/97 (40.2%) 80/225 (35.6%) 50/145 (34.5%) 69/195 (35.4%)
Pregnancy per ET cycle 39/81 (48.1%) 80/203 (39.4%) 50/130 (38.5%) 69/137 (50.4%)
Live birth per ET cycle 27/81 (33.3%) 57/203 (28.1%) 40/130 (30.8%) 58/137 (42.3%)
Miscarriage per pregnancy 10/39 (25.6%)* 18/80 (22.5%) 4/50 (8%) 8/69 (11.6%)
Multiple gestation per preg-
nancy 8/39 (20.5%) 18/80 (22.5%) 13/50 (26.0%) 20/69 (29.0%)
OHSS
  7/97 (7.4%)*
  26/226 (11.5%)*
  23/146 (15.9%)
  43/195 (21.9%)
 
Values are numbers (percentages) of cycles, or mean ± standard deviation.
n = number of cycles of in-vitro fertilization
OR: Oocyte retrieval
ET: Embryo transfer
OHSS: Ovarian hyperstimulation syndrome
*
(p<0.05) indicates significant difference vs. Group 4
J Exp Clin Assist Reprod 2009;6:5 Kong, et al. 6 (page number not for citation purposes)
J Exp Clin Assist Reprod 2009;6:5 Kong, et al.
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
&
 
C
l
i
n
i
c
a
l
 
A
s
s
i
s
t
e
d
 
R
e
p
r
o
d
u
c
t
i
o
nquantity of oocyte retrieval in term of number and maturity
of oocytes retrieved. We specifically investigated the rela-
tionship between the proportion of mature oocyte per
oocyte retrieved and the serum E2 levels, and found that
there were no significant associations between them. This
observation suggests that the higher E2 levels only result
in more oocytes (and so an increased number of mature
oocytes proportionally), but does not promote the matu-
ration of oocytes per se. Concerning 2pn fertilization, our
study did not observe any significant differences in fertil-
ization rates among the four groups with different levels
of serum E2. Thus, our findings showed high serum E2
were associated with a better ovarian response but had no
effect on fertilization rate itself.
Although some studies have commented on the increased
embryo yield in patients with high serum E2 levels [3,9],
ours is the first description of the impact of serum E2 levels
on embryo quality. In this investigation, we found that
high serum E2 levels were associated with increased num-
ber of viable embryos and good-quality embryos per
cycle. However, the proportion of viable embryos per fer-
tilized embryo was indeed lower in the group with high
E2 levels. These observations suggest that high E2 levels
are associated with more oocytes retrieved and so more
viable or good-quality embryos proportionally, but they
are not associated with improvement in the quality of
embryo. Therefore, we do not anticipate any impact of
these high serum E2 levels on the outcome of the subse-
quent cryopreserved embryo cycles. However, this ques-
tion remains to be answered in further analysis.
The impact of high E2 level (measured on day of hCG
administration) on implantation is controversial. Some
authors have reported that high E2 level could be associ-
ated with no change or even an increased implantation rate
[9,11,13,14], while others reported a detrimental effect
and impaired implantation [1,2,15,16]. Arslan et al ana-
lyzed the cumulative E2 effect (using the “area under the
curve” approach) which maybe a better reflection of the
total E2 exposure of both oocytes and endometrium [17].
In parallel with our work, they found that different levels
of E2 exposure did not likely affect oocyte and embryo
quality [17]. However, they demonstrated detrimental
effects of high cumulative E2 exposure on embryo implan-
tation [17]. Postulated mechanisms for reduced implanta-
tion include impaired endometrial receptivity [17,18],
altered E2 to progesterone ratio [19], and reduction in the
nuclear receptor for E2 and progesterone in endometrial
stroma and glands [20]. Morphological and biochemical
changes in secretory endometrium have also been dem-
onstrated [21–24]. Within the safety range for OHSS in
our clinical practice, we indeed demonstrated a positive
effect of high serum E2 levels on IVF outcome in terms of
a higher implantation rate and a lower miscarriage rate,
which is a reflection of endometrial receptivity.
In conclusion, we have found that a high serum E2 level
at the time of hCG administration is a marker of a robust
ovarian response to controlled ovarian hyperstimulation
and is accompanied by more mature follicles, more mature
oocytes retrieved, and a higher yield of viable and good-
quality embryos. There is no significant impact of serum
E2 level on fertilization rate, maturation of oocytes and
quality of embryo per se, or the overall pregnancy rates.
The high E2 level did not adversely affect the endometrial
receptivity but indeed is associated with a higher implan-
tation rate and a lower miscarriage rate.
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